RAD News and Press, Rite Aid Corporation From 04/14/22

Rite Aid (RAD +7.6%) shows Q4 revenue of $6.06M, beats consensus by $110M. Bifurcating revenue: pharmacy services segment $1.7B (-9.4% Y/Y); pharmacy services segment $7.3B (-8.1% Y/Y) Q4 net loss from continuing operations of $389.1M, or EPS loss of $7.18; adjusted net loss from co...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rite Aid (NYSE: RAD ) stock is rising higher on Thursday thanks to the company’s results from its earnings report for the fourth quarter of fiscal 2022. Source: Jonathan Weiss / Shutterstock.com The good ...

Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...

Rite Aid Corporation stock ( NYSE: RAD ) opened more than 15% in premarket trading on Thursday after the pharmacy company reported strong revenue for its fiscal Q4 and gave better than expected guidance for the full year. Key takeaways from Rite Aid Q4 earnings report Net loss...

Dolphin Entertainment (DLPN) +26% on FY results. Airgain (AIRG) +13% on multimillion-dollar contract by major utility. CBAK Energy Technology (CBAT) +12% on Q4 results. Takung Art (TKAT) +8%. Veru (VERU) +7% breather over as stock gains. Metromile (MILE...

Rite Aid press release (NYSE:RAD): Q4 Non-GAAP EPS of -$1.63 misses by $1.06. Revenue of $6.07B (+2.5% Y/Y) beats by $110M. FY2023 guidance: Revenues to be between $23.1B-$23.5B vs. consensus of $23.44B; Adjusted EBITDA of $460M-$500M; Adjusted EPS of -$1.06 to -$0.53 vs. consensus of -$1.94 ...

Full Year Revenues Increased $525 million to $24.6 billion; Pharmacy Sales Increased 12% Full Year Net Loss per Share Increased from $1.87 to $9.96 Driven by Non-Cash Impairment Charges Full Year Adjusted EBITDA Increased 16% to $505.9 million Driven by Strong Retail...

Rite Aid (NYSE:RAD) consensus EPS estimate is -$0.57 and consensus revenue estimate is $5.95B. Over the last 2 years, the drugstore chain has beaten EPS estimates 100% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have ...

Rite Aid (NYSE:RAD) shares have lost half their value since January -- a far worse performance than rival drug store chains have seen. The slide has come amid heightened concerns about the company’s future, with some analysts predicting even more declines to come. With the company set ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...